eligibility_summary
Adults ≥18 with RRMM, ECOG 0–1, ≥12‑wk life expectancy, adequate labs, post–standard‑of‑care BCMA CAR‑T 6–10 wks prior without progression (ide‑cel: ≥2 prior lines, cilta‑cel: ≥2, or 1 and lenalidomide‑refractory/intolerant). Bone marrow sampling required, non‑heme AEs ≤G1, contraception. Exclude: severe CAR‑T toxicities (≥G3 CRS, any ICANS/MAS/HLH, movement/neurocog), recent immunotherapy/chemo/immunosuppression/transplant, autoimmune/CNS/cardiac/pulmonary disease, active infection (HBV/HCV/HIV), recent surgery, live vaccines, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm trial of cevostamab consolidation after standard BCMA-directed CAR T in relapsed/refractory multiple myeloma. Intervention: Cevostamab, an IV T‑cell–engaging bispecific monoclonal antibody (TCE) that binds CD3 on T cells and FcRH5/FCRL5 on myeloma cells. Mechanism: bridges T cells to FcRH5+ plasma cells, forming an immune synapse that activates TCR/CD3 signaling, drives cytokine release and perforin/granzyme-mediated killing, potentially clearing BCMA-escaped clones post-CAR T. Targets: malignant plasma cells expressing FcRH5, effector CD3+ T cells (TCR/CD3 pathway). Given Q3W starting ~10 weeks post-CAR T. Goal: increase 12‑month MRD‑negative CR.